Musculoskeletal Tumor Surgery

Tampa General Hospital's Orthopaedic Institute Recognized as a Top Orthopaedic Program by Becker's Hospital Review for 2023

Retrieved on: 
Monday, November 13, 2023
Foot, Health, Hip, Orthopedic surgery, Trauma center, Research, Nursing, Becker's, Becker's Hospital Review, Musculoskeletal Tumor Surgery, Hip fracture, Hospital, Orthopaedic nursing, Shoulder, Patient, Ankle, Knee, National Association, Tampa General Hospital, Rehabilitation, News, Partnership, 3D, Physician, Injury, Arthritis, TGH

TAMPA, Fla., Nov. 13, 2023 /PRNewswire/ -- Tampa General Hospital (TGH)'s Orthopaedic Institute is one of the top orthopaedic programs in the U.S., according to Becker's Hospital Review's 2023 list of "100 Hospitals and Health Systems with Great Orthopedic Programs," which highlights hospitals and health systems with orthopaedic programs that provide exceptional orthopaedic care for patients with musculoskeletal conditions or injuries. This recognition underscores Tampa General's commitment to delivering best-in-class orthopaedic care, placing the TGH Orthopaedic Institute among a cohort of orthopaedic programs treating a high volume of patients, conducting research that advances the field of orthopaedics and using the most cutting-edge technologies available.

Key Points: 
  • TAMPA, Fla., Nov. 13, 2023 /PRNewswire/ -- Tampa General Hospital (TGH)'s Orthopaedic Institute is one of the top orthopaedic programs in the U.S., according to Becker's Hospital Review's 2023 list of "100 Hospitals and Health Systems with Great Orthopedic Programs," which highlights hospitals and health systems with orthopaedic programs that provide exceptional orthopaedic care for patients with musculoskeletal conditions or injuries.
  • "At Tampa General, our team consistently raises the bar for the level of care and innovation our patients can expect from a nationally recognized academic health system," said John Couris, president and CEO of Tampa General Hospital.
  • The TGH Orthopaedic Institute is the leading provider of orthopaedic care in the West Central Florida region, performing more than 5,000 procedures annually.
  • As Tampa Bay's only Level I Trauma Center, Tampa General also offers emergency orthopaedic care and reconstructive surgery for traumatic injuries.

IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®

Retrieved on: 
Monday, August 29, 2022
Commerce, CE marking, Breast cancer, Breast, Privacy Office of the U.S. Department of Homeland Security, Ministry, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Securities & Exchange Commission of Pakistan, Liver, NASDAQ, Kidney, World, Risk, Food, Department, U.S. Department of Commerce Office of Security, SEC, Lung, Musculoskeletal Tumor Surgery, Device file, Kidney cancer, Company, Cancer, U.S. Securities and Exchange Commission, Ministry of Health and Medical Education, Neoplasm, List of health departments and ministries, Genta (company), TASE, Annual report, Private Securities Litigation Reform Act, Freezing, World Health Organization, Medical device, Medical imaging, Health

CAESAREA, Israel, Aug. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has submitted a regulatory filing with the Department of Medical Equipment and Construction ("DMEC") of Vietnam's Ministry of Health for the ProSense System and accessories.

Key Points: 
  • Liver, lung, and breast cancer were the three most prevalent cancers in Vietnam in 2020 according to the World Health Organization.
  • "Asia is a significant market for ProSense and Vietnam is one of the fastest growing healthcare markets in the region.
  • Having started the regulatory process in Vietnam, we anticipate high interest from potential distributors in the country," stated IceCure CEO, Eyal Shamir.
  • For example, IceCure is using forward looking statements in this press release when it discusses its regulatory approval process in Vietnam for various indications through the Ministry of Health's DMEC, potential high interest from potential distributors in the country.

RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer

Retrieved on: 
Wednesday, January 19, 2022
FDA, Hospitals, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Oncology, Securities Exchange Act of 1934, Survival, Nature, Musculoskeletal Tumor Surgery, Patient, Technology, FSVM, Research, Conference, Interventional radiology, Cholangiocarcinoma, Forward-looking statement, COVID-19, Effectiveness, Safety, Securities Act of 1933, Absorption, Intellectual property, Nobu, Pancreatic cancer, Metabolism, U.S. Securities and Exchange Commission, FIU Herbert Wertheim College of Medicine, Liver disease, Industry, Quality of life, Hepatocellular carcinoma, Florida International University, PI, Cancer, Neoplasm, FDA, Lung cancer, Principal, Security (finance), Drug Quality and Security Act, Nobu Hotel Barcelona, Terminology, Medical device, Medical imaging, Pharmaceutical industry, Pancreas, LAPC, the 2022 SPECTRUM Conference, RenovoRx, Inc., THE 2022 SPECTRUM CONFERENCE, RENOVORX, INC.

The 2022 SPECTRUM conference was held last weekend, January 14-16, 2022, at the Nobu Hotel in Miami Beach, Florida.

Key Points: 
  • The 2022 SPECTRUM conference was held last weekend, January 14-16, 2022, at the Nobu Hotel in Miami Beach, Florida.
  • Dr. Gandhis presentation at the 2022 SPECTRUM Conference provides an overview of the RenovoTAMP platform and supportive published research.
  • This data suggests that by using RenovoTAMP for targeted delivery of chemotherapy, the systemic impacts of chemotherapy may be being reduced.
  • RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.

Targeted Oncology™ Adds Two New Premier Oncology Association Partners to Its Strategic Alliance Partnership Program

Retrieved on: 
Tuesday, March 16, 2021
Research, Nursing, Surgery, Other Health, Radiology, Health, Other Science, Science, Oncology, Medical specialties, Oncology, Medicine, Health care, Surgical oncology, Musculoskeletal Tumor Surgery

We are pleased to see continuing collaboration between such prominent organizations in the field of oncology through the Strategic Alliance Partnership (SAP) program, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of Targeted Oncology.

Key Points: 
  • We are pleased to see continuing collaboration between such prominent organizations in the field of oncology through the Strategic Alliance Partnership (SAP) program, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of Targeted Oncology.
  • Each partner in the SAP program has the same common goal: improving the quality of life for all patients.
  • Virginia Cancer Specialists offers medical oncology, radiation oncology, musculoskeletal tumor surgery, breast surgery, thoracic surgery, genetic counseling, palliative care, oncology nurse navigators, oncology infusion nurses, oncology pharmacists, social workers, dietitians and laboratory technicians.
  • TargetedOnc.com , the website for Targeted Oncology, provides practicing oncologists with the latest news and insights on next-generation therapeutics and their molecular targets.